ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARP Annual Meeting 2019

Abstract Number: 1053

Parallel Analysis of Systemic Sclerosis and Keloidal Morphea Skin Biopsies Delineates the Hallmark Profibrotic Gene Expression Profile for Scleroderma in Vivo

Kristina Clark1, Corrado Campochiaro 1, Nataliya Gak 1, Emma Derrett-Smith 1 and Christopher Denton 2, 1University College London, London, United Kingdom, 2University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARP Annual Meeting 2019

Keywords: Gene Expression, Morphea, Scleroderma, systemic sclerosis and pathogenesis

Session Information

Date: Monday, November 11, 2019

Title: Systemic Sclerosis & Related Disorders – Basic Science Poster

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: We have examined whole skin biopsy gene expression by RNAseq in a rare subgroup of scleroderma with both systemic sclerosis (SSc) and concurrent keloidal morphea (KM).  We hypothesised that this subtype of localised scleroderma would provide exceptional insight into fibroblast activation in vivo relevant to skin fibrosis in systemic sclerosis and suggest new potential molecular markers for classification.

Methods: 4mm skin biopsies were taken from forearm skin of SSc cases classified as limited (lcSSc) (n=5) or diffuse (dcSSc) (n=7).  All patients met ACR/EULAR criteria for classification of SSc. In 4 cases there was concurrent KM and 4mm skin were also taken from these lesions.  Control biopsies were taken from forearm skin of healthy individuals (HC) (n=4).  Whole genome expression analysis was performed by RNAseq.  Data were normalised and scaled. Gene expression analysis was undertaken and differentially expressed genes were compared across the clinical subgroups using ANOVA with Benjamini-Hochberg post-hoc correction. The 500 most differentially expressed genes were identified, and unsupervised clustering was performed using CIMminer (Bethesda, Maryland, USA). Integration of the candidate genes from ANOVA, and principal component analysis (PCA) was carried out to identify instructive genes for a molecular classifier. 

Results: RNAseq identified over 13000 expressed genes. PCA discriminated 4 unique clusters, with keloidal morphea and HCs being the most distinct. PC1 accounted for 33% and PC2 for 22% of variation. Initial analysis identified over 3000 significantly different genes expressed by paired analysis. The 500 most significantly differentially expressed genes (all with p< 0.001) were selected. Unsupervised hierarchical clustering of gene expression based on these results, showed clear clustering of the keloidal morphea group, and the HCs. The majority of lcSSc and dcSSc patients clustered to their patient subgroups (Figure 1). Correlation between ANOVA and PCA results highlighted 100 key genes shared across both analysis results.  These included genes upregulated in SSc: SFRP4, THY1, COMP, ADAM12, THBS4, ADAMTS12 (table 1) and others with lower expression than in HC: WIF1, KLF5.  These include several implicated in pathogenesis or included in recent candidate biomarkers for skin disease in SSc.

Conclusion: We show the high value of RNAseq and the unique strength using skin biopsies from SSc with concurrent keloidal morphea, histologically characterised by dense fibro-proliferation, to define profibrotic genes relevant to SSc.   This provides powerful insight into pathogenesis and candidate molecular markers for classification across the scleroderma spectrum.

Figure 1: Unsupervised hierarchical clustering of differentially genes across scleroderma spectrum confirms potential utility of these genes in subset classification. Key: HC -healthy control-, KM -keloidal morphea-

Table 1: Sample scleroderma genes showing altered expression in keloidal morphea and systemic sclerosis.


Disclosure: K. Clark, None; C. Campochiaro, None; N. Gak, None; E. Derrett-Smith, None; C. Denton, Actelion, 5, Actelion Pharmaceuticals, 5, Actelion, GlaxoSmithKline, Bayer, Sanofi, lnventiva, Boehringer Ingelheim, Roche, Bristol Myers Squibb, CSL Behring, UCB, Leadiant Biosciences, 5, Bayer, 5, Boehringer Ingelheim, 5, Bristol Myers Squibb, 5, Bristol-Myers Squibb, 5, Corbus Pharmaceuticals, 5, CSL Behring, 2, 5, GlaxoSmithKline, 2, 5, Inventiva, 2, 5, Leadiant Biosciences, 2, 5, lnventiva, 5, Pfizer, 5, Roche, 5, Sanofi, 5, UCB, 5.

To cite this abstract in AMA style:

Clark K, Campochiaro C, Gak N, Derrett-Smith E, Denton C. Parallel Analysis of Systemic Sclerosis and Keloidal Morphea Skin Biopsies Delineates the Hallmark Profibrotic Gene Expression Profile for Scleroderma in Vivo [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/parallel-analysis-of-systemic-sclerosis-and-keloidal-morphea-skin-biopsies-delineates-the-hallmark-profibrotic-gene-expression-profile-for-scleroderma-in-vivo/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/parallel-analysis-of-systemic-sclerosis-and-keloidal-morphea-skin-biopsies-delineates-the-hallmark-profibrotic-gene-expression-profile-for-scleroderma-in-vivo/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology